Peripheral Blood Progenitor T Cell Generation via Magnetic Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating T cells from peripheral blood progenitor cells are not simple or cost-effective, and existing techniques do not accurately reflect natural T cell generation mechanisms in humans, limiting their application in therapies such as CAR T cell treatments for cancers.
Innovation Solution
A novel method involving the isolation and cultivation of peripheral blood mononuclear cells using anti-coagulant-containing blood collection tubes, FICOLL gradient centrifugation, and magnetic bead-based selection to generate T cells, followed by lentiviral transduction for chimeric antigen receptor (CAR) gene introduction, allowing for the expansion and purification of T cells for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods (FTOC or OP9-DL1) are used to generate T cells from HSCs, then T cells can be obtained, but the process is complex, costly, and does not reflect natural human T cell generation mechanisms
Solution Approach 1:
The patent extracts and isolates the specific CD3-CD14- progenitor cell population from peripheral blood that naturally gives rise to T cells, removing the need for complex thymic organ cultures or specialized stromal cell lines. This extraction of the key functional component simplifies the system while maintaining biological fidelity to natural human T cell development
Solution Approach 2:
The patent creates a simplified in vitro model that copies the essential features of natural human T cell development by culturing CD3-CD14- progenitors with appropriate cytokines, producing T cells that reflect natural human mechanisms without requiring replication of the entire thymic environment
2Ease of manufacture
If T cells are obtained from peripheral blood using conventional separation methods, then T cells can be isolated, but the process is not cost-effective and lacks simplicity
Solution Approach 1:
The patent performs preliminary enrichment of CD3-CD14- progenitor cells from peripheral blood using magnetic bead selection before culture expansion. This preliminary action concentrates the target population, simplifying subsequent culture steps and improving overall process efficiency while reducing costs by eliminating the need for complex downstream separation procedures
Solution Approach 2:
The patent changes the key parameter from attempting to isolate mature T cells directly to instead enriching and expanding CD3-CD14- progenitor cells, which naturally differentiate into T cells in culture. This parameter change simplifies the isolation process and improves cost-effectiveness while maintaining high productivity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the de novo generation of T cells and CAR T cells from peripheral blood progenitor cells, providing a cost-effective and reliable approach for therapeutic applications, including cancer treatment, by ensuring high purity and functionality of the generated cells.
Implementation Method 1
magnetic bead-based selection to generate T cells
Implementation Method 2
FICOLL gradient centrifugation
Data Source
AI summary
The present invention describes a novel method of generating the T cells from the cell fraction obtained from human peripheral blood mononuclear cells or peripheral blood progenitor cells or peripheral blood precursors. The present invention also provides a novel method of generating CAR T cells (chimeric antigen receptor) using the T cells generated from specific cell fraction and a novel method of generating engineered or modified T cell ex vivo.